VVOS logo

VIVOS THERAPEUTICS INC

VVOSNASDAQ
πŸ† #5018 by market capEarnings Apr 13US Equity
$0.05β–Ό $0.00 (βˆ’5.10%)
Market closed Β· at close
πŸ””
Track VVOS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.1%
7dβ–Ό 43.2%
14dβ–Ό 42.3%
30dβ–Ό 58.8%
ytdβ–Ό 97.3%
1yβ–Ό 97.6%
🏦Market Cap
$2M
Small Cap
πŸ“ˆRevenue Growth (YoY)
45.2%
High Growth
πŸ“ŠGross Margin
61.9%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.1x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.05 – $0.06
52-Week Range
$0.05 – $2.69
Volume (shares)
1,435,489
Avg Volume (shares)
β€”
Shares Outstanding
33.6M
Next Earnings
2027-04-13

Fundamentals Snapshot

Annual Revenue
$17M
Last Q Revenue
$5M
P/E Ratio
β€”
P/S Ratio
0.1x
EPS (TTM)
$-1.88
Dividend Yield
β€”
Dilution (1yr)
+57.7%
VVOS logo

VIVOS THERAPEUTICS INC

VVOS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17Mβ–² +16.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
60.4%β–² +0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$20Mβ–² +78.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$18Mβ–² +32.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.3Mβ–² +57.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$11Mβ–Ό βˆ’$16M YoY
StockOtter Β· stockotter.space

About VIVOS THERAPEUTICS INC

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

Defense WorldΒ·3d ago

Vivos Therapeutics Q3 Earnings Call Highlights

Vivos Therapeutics (NASDAQ: VVOS) reported lower third-quarter revenue and a narrower net loss as it reduced expenses and shifted its business toward sleep centers. The company also warned that its cash balance was insuf

Seeking AlphaΒ·5d ago

Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript

Vivos Therapeutics, Inc. ( VVOS ) Q3 2026 Earnings Call November 16, 2026 5:00 PM EST Company Participants Roman Franklin - Chief Financial Officer R. Huntsman - Co-Founder, Chairman of the Board & CEO Presentation Opera

Zacks Investment ResearchΒ·6d ago

Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.49 per share a year ago.

GlobeNewsWireΒ·6d ago

Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update

Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders' equity requirement

GlobeNewsWireΒ·Oct 21

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard

LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (β€œVivos” or the β€œCompany”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnosti

GlobeNewsWireΒ·Oct 19

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More Than $10 Million to St